(EVOK) Evoke Pharma - Overview
Stock: Nasal Spray, Diabetic Gastroparesis
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 162% |
| Relative Tail Risk | -35.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.38 |
| Alpha | 416.76 |
| Character TTM | |
|---|---|
| Beta | 0.407 |
| Beta Downside | -0.161 |
| Drawdowns 3y | |
|---|---|
| Max DD | 95.46% |
| CAGR/Max DD | -0.18 |
Description: EVOK Evoke Pharma December 31, 2025
Evoke Pharma, Inc. (NASDAQ:EVOK) is a specialty pharmaceutical firm that develops and commercializes treatments for gastro-enterological disorders. Its lead product, Gimoti-a metoclopramide nasal spray-targets acute and recurrent diabetic gastroparesis in adults, and the company distributes primarily to gastroenterologists, internal medicine specialists, primary-care physicians, and select health-care providers. As of December 15 2025, Evoke operates as a subsidiary of QOL Medical, LLC, after being incorporated in 2007 and headquartered in Solana Beach, California.
Key performance indicators as of the latest quarter (Q3 2025) show a market capitalization of roughly $30 million, cash and cash equivalents of $12 million, and a net loss of $4.2 million, reflecting a burn rate of about $1.4 million per month. The company’s pipeline remains thin, with Gimoti as the sole commercial product and a Phase 2 trial underway for a delayed-release formulation of the same molecule. The gastro-enterology market is buoyed by an aging U.S. population and an estimated 4 % prevalence of gastroparesis among diabetics, driving modest but steady demand for niche therapies.
For a deeper quantitative look at EVOK’s valuation metrics and peer comparison, the ValueRay platform provides a concise data snapshot worth reviewing.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: -5.23m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.21 > 0.02 and ΔFCF/TA 16.38 > 1.0 |
| NWC/Revenue: 22.85% < 20% (prev 49.57%; Δ -26.73% < -1%) |
| CFO/TA -0.21 > 3% & CFO -3.32m > Net Income -5.23m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.27 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.56m) vs 12m ago 82.69% < -2% |
| Gross Margin: 97.02% > 18% (prev 0.97%; Δ 9606 % > 0.5%) |
| Asset Turnover: 96.80% > 50% (prev 60.88%; Δ 35.92% > 0%) |
| Interest Coverage Ratio: -2.21 > 6 (EBITDA TTM -4.73m / Interest Expense TTM 500.0k) |
Altman Z'' -15.00
| A: 0.21 (Total Current Assets 15.5m - Total Current Liabilities 12.2m) / Total Assets 15.6m |
| B: -8.49 (Retained Earnings -132.8m / Total Assets 15.6m) |
| C: -0.07 (EBIT TTM -1.10m / Avg Total Assets 14.9m) |
| D: -10.81 (Book Value of Equity -132.8m / Total Liabilities 12.3m) |
| Altman-Z'' Score: -38.14 = D |
What is the price of EVOK shares?
Over the past week, the price has changed by +3.42%, over one month by +14.73%, over three months by +141.77% and over the past year by +430.07%.
Is EVOK a buy, sell or hold?
- StrongBuy: 0
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the EVOK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 18 | -30% |
| Analysts Target Price | 18 | -30% |
| ValueRay Target Price | 28.2 | 9.5% |
EVOK Fundamental Data Overview February 01, 2026
P/B = 5.6351
P/EG = -0.1
Revenue TTM = 14.4m USD
EBIT TTM = -1.10m USD
EBITDA TTM = -4.73m USD
Long Term Debt = 112.3k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 5.07m USD (from shortTermDebt, last quarter)
Debt = 5.11m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -6.46m USD (from netDebt column, last quarter)
Enterprise Value = 12.5m USD (18.9m + Debt 5.11m - CCE 11.6m)
Interest Coverage Ratio = -2.21 (Ebit TTM -1.10m / Interest Expense TTM 500.0k)
EV/FCF = -3.75x (Enterprise Value 12.5m / FCF TTM -3.32m)
FCF Yield = -26.63% (FCF TTM -3.32m / Enterprise Value 12.5m)
FCF Margin = -23.05% (FCF TTM -3.32m / Revenue TTM 14.4m)
Net Margin = -36.23% (Net Income TTM -5.23m / Revenue TTM 14.4m)
Gross Margin = 97.02% ((Revenue TTM 14.4m - Cost of Revenue TTM 429.8k) / Revenue TTM)
Gross Margin QoQ = 97.62% (prev 95.53%)
Tobins Q-Ratio = 0.80 (Enterprise Value 12.5m / Total Assets 15.6m)
Interest Expense / Debt = 2.47% (Interest Expense 126.0k / Debt 5.11m)
Taxrate = 21.0% (US default 21%)
NOPAT = -871.6k (EBIT -1.10m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.27 (Total Current Assets 15.5m / Total Current Liabilities 12.2m)
Debt / Equity = 1.52 (Debt 5.11m / totalStockholderEquity, last quarter 3.36m)
Debt / EBITDA = 1.37 (negative EBITDA) (Net Debt -6.46m / EBITDA -4.73m)
Debt / FCF = 1.94 (negative FCF - burning cash) (Net Debt -6.46m / FCF TTM -3.32m)
Total Stockholder Equity = 5.15m (last 4 quarters mean from totalStockholderEquity)
RoA = -35.07% (Net Income -5.23m / Total Assets 15.6m)
RoE = -101.4% (Net Income TTM -5.23m / Total Stockholder Equity 5.15m)
RoCE = -20.95% (EBIT -1.10m / Capital Employed (Equity 5.15m + L.T.Debt 112.3k))
RoIC = -8.58% (negative operating profit) (NOPAT -871.6k / Invested Capital 10.2m)
WACC = 6.26% (E(18.9m)/V(24.1m) * Re(7.42%) + D(5.11m)/V(24.1m) * Rd(2.47%) * (1-Tc(0.21)))
Discount Rate = 7.42% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -12.54%
Fair Price DCF = unknown (Cash Flow -3.32m)
EPS Correlation: 17.47 | EPS CAGR: 19.67% | SUE: 0.0 | # QB: 0
Revenue Correlation: 98.60 | Revenue CAGR: 93.48% | SUE: -0.00 | # QB: 0
EPS next Year (2026-12-31): EPS=0.68 | Chg30d=+0.040 | Revisions Net=+1 | Growth EPS=+136.2% | Growth Revenue=+58.0%